AR076228A1 - Piperidinas sustituidas como antagonistas de ccr3 - Google Patents
Piperidinas sustituidas como antagonistas de ccr3Info
- Publication number
- AR076228A1 AR076228A1 ARP100101174A ARP100101174A AR076228A1 AR 076228 A1 AR076228 A1 AR 076228A1 AR P100101174 A ARP100101174 A AR P100101174A AR P100101174 A ARP100101174 A AR P100101174A AR 076228 A1 AR076228 A1 AR 076228A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- ring
- group
- alkylene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Proporcionar antagonistas de CCR3, más particularmente proporcionar composiciones farmacéuticas que comprenden un vehículo farmacéuticamente aceptable y una cantidad terapéuticamente eficaz de al menos uno de los compuestos reivindicados o una sal farmacéuticamente aceptable del mismo. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula 1, en la que A es CH2, O o N-alquilo C1-6; R1 se selecciona entre NHR1.1 o NMeR1.1, NHR1.2 o NMeR1.2, NHCH2-R1.3, NH-cicloalquilo C3-6, mientras que, opcionalmente, un átomo de carbono se reemplaza por un átomo de nitrogeno, mientras que el anillo está opcionalmente sustituido con uno o más restos seleccionados entre el grupo que consiste en alquilo C1-6, O-alquilo C1-6, NHSO2-fenilo, NHCONH-fenilo, halogeno, CN, SO2-alquilo C1-6 y COO-alquilo C1-6; un anillo bicíclico C9 o 10, mientras que uno o dos átomos de carbono se reemplazan por átomos de nitrogeno y el sistema anular se une mediante un átomo de nitrogeno a la estructura básica de formula 1 y mientras que el sistema anular está opcionalmente sustituido con uno o más restos seleccionados entre el grupo que consiste en alquilo C1-6, COO-alquilo C1-6, haloalquilo C1-6, O-alquilo C1-6, NO2, halogeno, CN, NHSO2-alquilo C1-6 y metoxifenilo; un grupo seleccionado entre NHCH(piridinil)CH2COO-alquilo C1-6 y NHCH(CH2O-alquil C1-6)-benzoimidazolilo, opcionalmente sustituido con halogeno o CN; o 1-aminociclopentilo, opcionalmente sustituido con metil-oxadiazol; R1.1 es fenilo, opcionalmente sustituido con uno o más restos seleccionados entre el grupo que consiste en alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, alquileno C1-6-OH, alquenileno C2-6-OH, alquinileno C2-6-OH, CH2CON(alquilo C1-6)2, CH2NHCONH-cicloalquilo C3-6, CN, CO-piridinilo, CONR1.1.1R1.1.2, COO-alquilo C1-6, N(SO2-alquilo C1-6)(CH2CON(alquilo C1-4)2) O-alquilo C1-6, O-piridinilo, SO2-alquilo C1-6, SO2-alquileno C1-6-OH, SO2-cicloalquilo C3-6, SO2-piperidinilo, SO2NH-alquilo C1-6, SO2N(alquilo C1-6)2, halogeno, CN, CO-morfolinilo, CH2-piridinilo o un anillo heterocíclico opcionalmente sustituido con uno o más restos seleccionados entre el grupo que consiste en alquilo C1-6, NHalquilo C1-6 y =O; R1.1.1 H, alquilo C1-6, cicloalquilo C3-6, haloalquilo C1-6, CH2CON(alquilo C1-6)2, CH2CO-azetindinilo, alquileno C1-6-cicloalquilo C3-6, CH2-piranilo, CH2-tetrahidrofuranilo, CH2-furanilo, alquileno C1-6-OH o tiadiazolilo, opcionalmente sustituido con alquilo C1-6; R1.1.2 H, alquilo C1-6 o SO2alquilo C1-6; o R1.1.1 y R1.1.2 forman juntos un anillo carbocíclico de cuatro, cinco o seis miembros, que contiene opcionalmente un N u O, que reemplaza un átomo de carbono del anillo, opcionalmente sustituido con uno o más restos seleccionados entre el grupo que consiste en alquilo C1-6, alquileno C1-4-OH, OH y =O; o R1.1 es fenilo, donde dos restos adyacentes forman juntos un anillo carbocíclico, aromático o no aromático, de cinco o seis miembros, que contiene opcional e independientemente de cualquier otro uno o dos N, S o SO2, que reemplaza un átomo de carbono del anillo, donde el anillo está opcionalmente sustituido con alquilo C1-4 o =O; R1.2 se selecciona entre heteroarilo, opcionalmente sustituido con uno o más restos seleccionados entre el grupo que consiste en alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, CH2COO-alquilo C1-6, CONR1.2.1R1.2.2, COR1.2.3, COO-alquilo C1-6, CONH2, O-alquilo C1-6, halogeno, CN, SO2N(alquilo C1-6)2 o heteroarilo opcionalmente sustituido con uno o más restos seleccionados entre el grupo que consiste en alquilo C1-6, heteroarilo, opcionalmente sustituido con un anillo carbocíclico no aromático de cinco o seis miembros que contiene independientemente de cualquier otro dos N, O, S o SO2, que reemplaza un átomo de carbono del anillo; un anillo bicíclico C9 o 10 aromático o no aromático, mientras que uno o dos átomos de carbono se reemplazan por N, O o S, cada uno opcionalmente sustituido con uno o más restos seleccionados entre el grupo que consiste en N(alquilo C1-6)2, CONH-alquilo C1-6 y =O; un anillo heterocíclico no aromático, opcionalmente sustituido con piridinilo; 4,5-dihidro-nafto[2,1-d]tiazol, opcionalmente sustituido con NHCO-alquilo C1-6, R1.2.1 H, alquilo C1-6, alquileno C1-6-cicloalquilo C3-6, alquileno C1-4-fenilo, alquileno C1-4-furanilo, cicloalquilo C3-6, alquileno C1-4-O-alquilo C1-4, haloalquilo C1-6 o un anillo carbocíclico no aromático de cinco o seis miembros, que contiene opcional e independientemente de cualquier otro uno o dos N, O, S o SO2, que reemplaza un átomo de carbono del anillo, opcionalmente sustituido con 4-ciclopropilmetil-piperazinilo; R1.2.2 H o alquilo C1-6; R1.2.3 un anillo carbocíclico no aromático de cinco o seis miembros, que contiene opcional e independientemente de cualquier otro uno o dos N, O, S o SO2, que reemplaza un átomo de carbono del anillo; R1.3 se selecciona entre fenilo, heteroarilo o indolilo, cada uno opcionalmente sustituido con uno o más restos seleccionados entre el grupo que consiste en alquilo C1-6, cicloalquilo C3-6, O-alquilo C1-6, O-haloalquilo C1-6, fenilo y heteroarilo; R2 se selecciona entre el grupo que consiste en alquileno C1-6-fenilo, alquileno C1-6-naftilo y alquileno C1-6-heteroarilo; cada uno opcionalmente sustituido con uno, dos o tres restos seleccionados entre el grupo que consiste en alquilo C1-6, haloalquilo C1-6, O-alquilo C1-6, O-haloalquilo C1-6 y halogeno; R3 es H o alquilo C1-6; R4 es H o alquilo C1-6 o R3 y R4 forman juntos un grupo CH2-CH2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09157653 | 2009-04-08 | ||
EP09174917 | 2009-11-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR076228A1 true AR076228A1 (es) | 2011-05-26 |
Family
ID=42561233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100101174A AR076228A1 (es) | 2009-04-08 | 2010-04-07 | Piperidinas sustituidas como antagonistas de ccr3 |
Country Status (31)
Country | Link |
---|---|
US (3) | US8278302B2 (es) |
EP (1) | EP2417120B1 (es) |
JP (1) | JP5466246B2 (es) |
KR (1) | KR101690979B1 (es) |
CN (1) | CN102388032B (es) |
AP (1) | AP2989A (es) |
AR (1) | AR076228A1 (es) |
AU (1) | AU2010233849B2 (es) |
BR (2) | BRPI1013821B1 (es) |
CA (1) | CA2753151C (es) |
CL (1) | CL2011002197A1 (es) |
CO (1) | CO6501183A2 (es) |
DK (1) | DK2417120T3 (es) |
EA (1) | EA021072B1 (es) |
EC (1) | ECSP11011427A (es) |
ES (1) | ES2613696T3 (es) |
GE (1) | GEP20135863B (es) |
HK (1) | HK1164295A1 (es) |
HU (1) | HUE030787T2 (es) |
IL (1) | IL214309A (es) |
MA (1) | MA33178B1 (es) |
MX (1) | MX2011010584A (es) |
MY (1) | MY161903A (es) |
NZ (1) | NZ594597A (es) |
PE (1) | PE20120135A1 (es) |
PL (1) | PL2417120T3 (es) |
PT (1) | PT2417120T (es) |
SG (2) | SG10201401347QA (es) |
TW (1) | TWI466880B (es) |
UY (1) | UY32547A (es) |
WO (1) | WO2010115836A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
UA109290C2 (uk) * | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
WO2013079696A1 (en) * | 2011-12-01 | 2013-06-06 | Glaxo Group Limited | Methods of treatment and prevention of eye diseases |
US8680280B2 (en) | 2012-04-02 | 2014-03-25 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of CRR inhibitors |
US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
EP2881394B1 (en) | 2012-07-31 | 2018-03-21 | Kyowa Hakko Kirin Co., Ltd. | Condensed ring heterocyclic compound |
JP6382816B2 (ja) * | 2013-07-24 | 2018-08-29 | 田辺三菱製薬株式会社 | 眼科疾患治療剤 |
US10752640B2 (en) * | 2014-08-01 | 2020-08-25 | Nuevolution A/S | Compounds active towards bromodomains |
EP3613435A1 (en) | 2015-01-28 | 2020-02-26 | Universite De Bordeaux | Chemokine receptor cxcr4 inhibitors for treating and/or preventing chronic obstructive pulmonary disease |
WO2017170996A1 (ja) * | 2016-03-31 | 2017-10-05 | 国立研究開発法人国立長寿医療研究センター | 歯科用前処理材及び歯組織再生キット |
CN110650740A (zh) * | 2017-04-05 | 2020-01-03 | 万能溶剂有限公司 | 使用ccr3抑制剂治疗视网膜相关疾病的方法和组合物 |
JP2020513005A (ja) * | 2017-04-05 | 2020-04-30 | アルカヘスト,インコーポレイテッド | Ccr3阻害剤を用いて、加齢性機能障害を治療するための方法及び組成物 |
US20200054622A1 (en) * | 2017-04-05 | 2020-02-20 | Alkahest, Inc. | Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors |
JP7377718B2 (ja) | 2017-05-12 | 2023-11-10 | エナンタ ファーマシューティカルズ インコーポレイテッド | アポトーシスシグナル調節キナーゼ1阻害剤およびその使用方法 |
WO2019046186A1 (en) | 2017-08-28 | 2019-03-07 | Enanta Pharmaceuticals, Inc. | INHIBITORS OF KINASE 1 REGULATING THE APOPTOTIC SIGNAL CONTAINING TETRAZOLES AND METHODS OF USE THEREOF |
CN107602457A (zh) * | 2017-10-10 | 2018-01-19 | 重庆奥舍生物化工有限公司 | 一锅法合成6‑甲基‑2‑氨基‑异烟酸的方法 |
JP2020536929A (ja) * | 2017-10-13 | 2020-12-17 | アルカヘスト,インコーポレイテッド | Ccr3阻害剤を用いた、そう痒症、乾皮症、及び関連疾患を治療するための方法及び組成物 |
EP3787621A4 (en) | 2018-05-02 | 2022-01-12 | Enanta Pharmaceuticals, Inc. | APOPTOSIS SIGNAL REGULATING KINASE 1 INHIBITORS CONTAINING TETRAZOLES AND METHODS OF USE THEREOF |
US10683289B2 (en) | 2018-05-02 | 2020-06-16 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
CA3097083A1 (en) | 2018-05-15 | 2019-11-21 | Alkahest, Inc. | Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase |
US10968199B2 (en) | 2018-08-22 | 2021-04-06 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
BR112021004938A2 (pt) * | 2018-09-26 | 2021-06-01 | Alkahest, Inc. | métodos e composições para tratamento de danos associados com o envelhecimento usando inibidores de ccr3 |
WO2020106707A1 (en) | 2018-11-19 | 2020-05-28 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
WO2020198214A1 (en) | 2019-03-25 | 2020-10-01 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
WO2023076679A1 (en) | 2021-11-01 | 2023-05-04 | Alkahest, Inc. | Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7907121L (sv) * | 1979-08-27 | 1981-02-28 | Astra Laekemedel Ab | Ftalimidinderivat |
JP2807577B2 (ja) * | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
US6433165B1 (en) | 1998-01-21 | 2002-08-13 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
US6140349A (en) | 1998-02-02 | 2000-10-31 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
JP2002501898A (ja) * | 1998-02-02 | 2002-01-22 | メルク エンド カムパニー インコーポレーテッド | ケモカイン受容体活性の環状アミン調節剤 |
AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
TW583185B (en) | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
DE10233366A1 (de) | 2002-07-23 | 2004-02-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | In 6-Stellung substituierte Indolinonderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
PE20040804A1 (es) | 2002-12-19 | 2004-12-31 | Boehringer Ingelheim Pharma | DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa |
CA2543419A1 (en) * | 2003-10-24 | 2005-05-06 | Leyi Gong | Ccr3 receptor antagonists |
EP1725235B1 (en) * | 2004-02-05 | 2009-04-15 | Schering Corporation | Piperidine derivatives useful as ccr3 antagonists |
WO2005095339A1 (en) | 2004-03-31 | 2005-10-13 | Pfizer Products Inc. | Dicyanopyrrolidines as dipeptidyl peptidase iv inhibitors |
JP2007537180A (ja) | 2004-05-13 | 2007-12-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規置換チオフェンカルボキサミド、それらの調製方法及び薬物としてのそれらの使用 |
MX2007004051A (es) | 2004-10-07 | 2007-05-24 | Boehringer Ingelheim Int | Pi3-quinasas. |
JP2006137718A (ja) * | 2004-11-12 | 2006-06-01 | Astellas Pharma Inc | インドール若しくはインダゾール誘導体 |
US8030003B2 (en) | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
DOP2006000051A (es) | 2005-02-24 | 2006-08-31 | Lilly Co Eli | Inhibidores de vegf-r2 y métodos |
JP3701964B1 (ja) | 2005-03-08 | 2005-10-05 | アステラス製薬株式会社 | キヌクリジン誘導体の新規な塩 |
WO2006118256A1 (ja) | 2005-04-28 | 2006-11-09 | Kyowa Hakko Kogyo Co., Ltd. | 2-アミノキナゾリン誘導体 |
BRPI0609899A2 (pt) | 2005-04-28 | 2010-05-11 | Boehringer Ingelheim International Gmbh | compostos para o tratamento de doenças inflamatórias, uso dos mesmos, formulações farmacêuticas, combinações medicamentosas e produtos intermediários |
WO2007116313A2 (en) | 2006-04-12 | 2007-10-18 | Pfizer Limited | Pyrrolidine derivatives as modulators of chemokine ccr5 receptors |
GB0701992D0 (en) | 2007-02-02 | 2007-03-14 | 7Tm Pharma As | Grehlin Receptor Modulators |
DE102007012284A1 (de) | 2007-03-16 | 2008-09-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
US8008092B2 (en) | 2007-10-09 | 2011-08-30 | University Of Kentucky Research Foundation | CCR3 inhibition for ocular angiogenesis and macular degeneration |
TW201000446A (en) | 2008-05-30 | 2010-01-01 | Astrazeneca Ab | New compounds useful in pain therapy |
US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
US8680280B2 (en) | 2012-04-02 | 2014-03-25 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of CRR inhibitors |
US20130261153A1 (en) | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
-
2010
- 2010-03-19 US US12/727,318 patent/US8278302B2/en not_active Ceased
- 2010-04-01 SG SG10201401347QA patent/SG10201401347QA/en unknown
- 2010-04-01 AP AP2011005817A patent/AP2989A/xx active
- 2010-04-01 WO PCT/EP2010/054396 patent/WO2010115836A1/en active Application Filing
- 2010-04-01 BR BRPI1013821-8A patent/BRPI1013821B1/pt active IP Right Grant
- 2010-04-01 MX MX2011010584A patent/MX2011010584A/es active IP Right Grant
- 2010-04-01 JP JP2011544062A patent/JP5466246B2/ja active Active
- 2010-04-01 ES ES10712432.3T patent/ES2613696T3/es active Active
- 2010-04-01 CA CA2753151A patent/CA2753151C/en active Active
- 2010-04-01 HU HUE10712432A patent/HUE030787T2/en unknown
- 2010-04-01 SG SG2011072626A patent/SG175079A1/en unknown
- 2010-04-01 PL PL10712432T patent/PL2417120T3/pl unknown
- 2010-04-01 PE PE2011001650A patent/PE20120135A1/es not_active Application Discontinuation
- 2010-04-01 BR BR122019017002-9A patent/BR122019017002B1/pt active IP Right Grant
- 2010-04-01 KR KR1020117023451A patent/KR101690979B1/ko active IP Right Grant
- 2010-04-01 GE GEAP201012448A patent/GEP20135863B/en unknown
- 2010-04-01 NZ NZ594597A patent/NZ594597A/en unknown
- 2010-04-01 DK DK10712432.3T patent/DK2417120T3/en active
- 2010-04-01 MY MYPI2011004829A patent/MY161903A/en unknown
- 2010-04-01 AU AU2010233849A patent/AU2010233849B2/en active Active
- 2010-04-01 PT PT107124323T patent/PT2417120T/pt unknown
- 2010-04-01 MA MA34225A patent/MA33178B1/fr unknown
- 2010-04-01 EA EA201101398A patent/EA021072B1/ru not_active IP Right Cessation
- 2010-04-01 CN CN201080015048.XA patent/CN102388032B/zh active Active
- 2010-04-01 EP EP10712432.3A patent/EP2417120B1/en active Active
- 2010-04-07 AR ARP100101174A patent/AR076228A1/es active IP Right Grant
- 2010-04-07 UY UY0001032547A patent/UY32547A/es not_active Application Discontinuation
- 2010-04-07 TW TW99110771A patent/TWI466880B/zh active
-
2011
- 2011-07-27 IL IL214309A patent/IL214309A/en active IP Right Grant
- 2011-08-28 EC EC2011011427A patent/ECSP11011427A/es unknown
- 2011-09-06 CL CL2011002197A patent/CL2011002197A1/es unknown
- 2011-09-29 CO CO11127672A patent/CO6501183A2/es active IP Right Grant
-
2012
- 2012-05-15 HK HK12104764.2A patent/HK1164295A1/xx unknown
- 2012-08-28 US US13/596,225 patent/US8653075B2/en active Active
-
2014
- 2014-02-07 US US14/175,082 patent/USRE45323E1/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR076228A1 (es) | Piperidinas sustituidas como antagonistas de ccr3 | |
AR054799A1 (es) | Derivados de oxindol | |
AR078152A1 (es) | Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden | |
AR065322A1 (es) | 2-aminooxazolinas comoligandos de taar1 | |
AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
CO5700774A2 (es) | Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa-1 | |
AR077434A1 (es) | Compuestos para la reduccion de produccion de beta - amiloide | |
AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
AR031556A1 (es) | Derivados de 3-(diarilmetilen)-8-azabiciclo[3.2.1] octano y composiciones farmaceuticas que los comprenden | |
AR048641A1 (es) | Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame | |
ECSP055867A (es) | Derivados de pirrolopirimidina | |
AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
CR8756A (es) | Derivados de acido carboxilico bencimidazolona | |
AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
AR066492A1 (es) | Derivados de imidazoquinolina, proceso para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de enfermedades virales, bacterianas, alergicas y distintos tipos de canceres. | |
AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
AR040047A1 (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6 | |
AR080074A1 (es) | Naftiridinas sustituidas y su uso como medicamentos | |
AR051795A1 (es) | Derivados de hidantoina inhibidores de metaloproteinasas | |
AR065583A1 (es) | Compuestos macrociclicos y composicion farmaceutica | |
AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR051796A1 (es) | Derivados de hidantoina como inhibidores de metaloproteinasas | |
ECSP11010901A (es) | Compuestos de amida útiles en terapia | |
BR9802804A (pt) | Compostos benzimidazol, benzoxazol e benzotiazol, processo para sua preparação e composições farmacéuticas contendo os mesmos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |